Trial Profile
Phase II study of ZIO-101 in advanced blood and bone marrow cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Darinaparsin (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alaunos Therapeutics; ZIOPHARM Oncology
- 18 Jul 2012 Additional trial location (India) added as reported by ClinicalTrials.gov.
- 18 Jul 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov.
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.